Scholarlink

Objective <p>Prognosis in small cell lung cancer (SCLC) remains poorly predicted by conventional staging and metabolic parameters. This study aimed to develop a positron emission tomography/computed tomography (PET/CT) based Radiomic Risk Score (Rad-Score), evaluate its independent prognostic value for overall survival (OS), and assess the clinical utility of an integrated model using Decision Curve Analysis (DCA).</p> Materials and methods <p>143 SCLC patients (120 male, 23 female) who underwent pre-treatment staging <sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG) PET/CT between January 2012 and June 2024 were included. Using LIFEx (v25.06.1), 129 Image Biomarker Standardisation Initiative (IBSI) compliant radiomic features were extracted alongside standard metabolic parameters (SUVmax, SUVmean, MTV, TLG). After eliminating highly correlated features (|r|&gt; 0.90), five key features were selected via tenfold cross-validation LASSO-Cox regression to construct the Rad-Score. Patients were stratified into Low and High Radiomic Risk groups. Independent prognostic factors were identified through Cox regression analyses, and the incremental value of the Rad-Score was assessed by hierarchical C-index comparisons and DCA.</p> Results <p>Median OS was 10.8&#xa0;months (95% CI: 8.2–13.3), with a mortality rate of 83.9%. Multivariable analysis identified the Radiomic Risk Group (HR: 2.12; 95% CI: 1.33–3.40; p = 0.002) and Curative CRT (HR: 0.17; 95% CI: 0.06–0.48; p &lt; 0.001) as independent prognostic factors. The C-index improved from 0.657 to 0.688 (p = 0.018) and to 0.701 with Rad-Score integration (p = 0.0017). DCA demonstrated superior net benefit at high threshold probabilities (≥ 65%).</p> Conclusion <p>The <sup>18</sup>F-FDG PET/CT-based Rad-Score independently predicts survival in SCLC beyond conventional staging and metabolic parameters. The integrated model provides meaningful incremental prognostic value; however, multicenter external validation is warranted prior to clinical implementation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Development of a 18F-FDG PET/CT-based radiomic risk score as an independent prognostic factor in small cell lung cancer

  • 期刊论文

  • 发表日期：

    2026年7月20日

查看全文
  • Kerim Şeker,
  • Mukaddes Yılmaz,
  • Eda Erdiş,
  • Zekiye Hasbek

摘要

Objective

Prognosis in small cell lung cancer (SCLC) remains poorly predicted by conventional staging and metabolic parameters. This study aimed to develop a positron emission tomography/computed tomography (PET/CT) based Radiomic Risk Score (Rad-Score), evaluate its independent prognostic value for overall survival (OS), and assess the clinical utility of an integrated model using Decision Curve Analysis (DCA).

Materials and methods

143 SCLC patients (120 male, 23 female) who underwent pre-treatment staging 18F-fluorodeoxyglucose (18F-FDG) PET/CT between January 2012 and June 2024 were included. Using LIFEx (v25.06.1), 129 Image Biomarker Standardisation Initiative (IBSI) compliant radiomic features were extracted alongside standard metabolic parameters (SUVmax, SUVmean, MTV, TLG). After eliminating highly correlated features (|r|> 0.90), five key features were selected via tenfold cross-validation LASSO-Cox regression to construct the Rad-Score. Patients were stratified into Low and High Radiomic Risk groups. Independent prognostic factors were identified through Cox regression analyses, and the incremental value of the Rad-Score was assessed by hierarchical C-index comparisons and DCA.

Results

Median OS was 10.8 months (95% CI: 8.2–13.3), with a mortality rate of 83.9%. Multivariable analysis identified the Radiomic Risk Group (HR: 2.12; 95% CI: 1.33–3.40; p = 0.002) and Curative CRT (HR: 0.17; 95% CI: 0.06–0.48; p < 0.001) as independent prognostic factors. The C-index improved from 0.657 to 0.688 (p = 0.018) and to 0.701 with Rad-Score integration (p = 0.0017). DCA demonstrated superior net benefit at high threshold probabilities (≥ 65%).

Conclusion

The 18F-FDG PET/CT-based Rad-Score independently predicts survival in SCLC beyond conventional staging and metabolic parameters. The integrated model provides meaningful incremental prognostic value; however, multicenter external validation is warranted prior to clinical implementation.